NAMS (NewAmsterdam Pharma Corp) Earnings growth in current year

NAMS (NewAmsterdam Pharma Corp) - company brandmark

The annual EPS growth rate demonstrates current dynamics, where 11.20 reflects the latest value of the metric. Currently, NewAmsterdam Pharma (NAMS) relies critically on the results of the final stage of tests for its primary cholesterol treatment. There is a possibility of more affordable alternatives emerging, which would create significant market barriers. However, success in metabolic therapy innovations will ensure a stable cash flow for years to come.

NAMS: NewAmsterdam Pharma Earnings per share growth in current year 06/21/2023 - 11/17/2026

Financial and market metric breakdowns for NewAmsterdam Pharma Company (NAMS)

Basic company analysis:NAMS - NewAmsterdam Pharma Corp
Finished products of NewAmsterdam Pharma Company N.V.

Investors must evaluate business resilience through net income per share dynamics, which measure the growth rate of real shareholder income relative to the previous year. By analyzing the annual EPS change ratio, one can confirm the commercialization efficiency of NewAmsterdam Pharma (NAMS) new lipid-lowering drugs, which replace traditional statins to reduce cardiac risks.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|SLNO: Earnings per share growth in current year|FOLD: Earnings growth in current year|ETNB - Expected net earnings per share growth this year|Earnings per share growth in current year Agios Corp|Structure Corp (GPCR) - Expected net earnings per share growth this year|Earnings per share growth in current year mimedx.com (MDXG)|Net earnings per share growth this year rezolutebio.com RZLT|Earnings per share growth in current year Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Earnings per share growth in current year|ALT: Net earnings per share growth this year|AARD - Earnings growth in current year|SGMT: Earnings growth in current year|Earnings per share growth rate in current year BioAge Labs, Inc. (BIOA)|Earnings per share growth in current year Biomea Fusion Inc|Earnings per share growth this year QNCX (Quince Therapeutics)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year